Skip to main content

Merck & Company(MRK-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Profile

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Key Executives

NameTitle
Richard R. DeLucaExecutive VP/President, Divisional
Robert M. DavisCEO/Chairman of the Board/Director/President
Betty D. LarsonExecutive VP/Other Executive Officer
Sanat ChattopadhyayExecutive VP/President, Divisional
Chirfi GuindoChief Marketing Officer/Senior VP, Divisional
Jennifer ZacharyExecutive VP/General Counsel
Caroline A. LitchfieldCFO/Executive VP
David Michael WilliamsChief Information Officer/Executive VP/Other Executive Officer
Dean Y. LiExecutive VP, Divisional/President, Divisional
Jannie OosthuizenPresident, Geographical/Senior VP
Joseph RomanelliPresident, Subsidiary/Senior VP
Dalton E. SmartChief Accounting Officer/Controller/Senior VP, Divisional
Brian FoardExecutive VP/President, Divisional
David R. MaraldoSenior VP, Divisional

More from The Globe